Skip to Main content Skip to Navigation
Journal articles

Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis

Abstract : Background: Mucormycosis incidence is increasing and is associated with a high rate of mortality. Although lipid-based formulations of amphotericin B are the recommended first-line treatment, only one prospective trial in a limited number of patients has been performed to evaluate this regimen. Methods: Patients with proven or probable mucormycosis were included between June 2007 and March 2011. Patients were scheduled to receive 10 mg/kg/day liposomal amphotericin B (L-AMB) monotherapy for 1 month and surgery was performed when appropriate. The primary outcome was response rate at week 4 or at the end of treatment (EOT) if before week 4, evaluated by an independent committee. ClinicalTrials.gov Identifier: NCT00467883. Results: Forty patients were enrolled. Response was analysed in 33 patients at week 4. Most patients had a haem-atological malignancy as their primary underlying disease (53%). Seventy-one percent of patients underwent therapeutic surgery. The response rate at week 4 or at EOT was 36%, with 18% partial responses and 18% complete responses. The response rate at week 12 was 45%, with 13% partial responses and 32% complete responses. Overall mortality was 38% at week 12 and 53% at week 24. Serum creatinine doubled in 16 (40%) patients and returned to normal levels within 12 weeks in 10/16 (63%). Conclusions: High-dose LAMB for mucormycosis, in combination with surgery in 71% of cases, was associated with an overall response rate of 36% at week 4 and 45% at week 12 and creatinine level doubling in 40% of patients (transient in 63%). These results may serve as the basis for future clinical trials.
Document type :
Journal articles
Complete list of metadatas

Cited literature [29 references]  Display  Hide  Download

https://hal-normandie-univ.archives-ouvertes.fr/hal-02317920
Contributor : Venceslas Villier <>
Submitted on : Thursday, October 24, 2019 - 9:49:03 AM
Last modification on : Wednesday, October 14, 2020 - 4:09:51 AM
Long-term archiving on: : Saturday, January 25, 2020 - 12:48:02 PM

File

lanternier2015 (1).pdf
Files produced by the author(s)

Identifiers

Citation

F. Lanternier, S. Poiree, C. Elie, D. Garcia-Hermoso, P. Bakouboula, et al.. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2015, 70 (11), pp.3116-3123. ⟨10.1093/jac/dkv236⟩. ⟨hal-02317920⟩

Share

Metrics

Record views

341

Files downloads

827